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Relationship of Paroxysmal Atrial Tachyarrhythmias to
Volume Overload
Assessment by Implanted Transpulmonary Impedance Monitoring
Rajat Jhanjee, MD, MS; Grant A. Templeton, BS; Srinivasan Sattiraju, MD; John Nguyen, MD, MPH;
Scott Sakaguchi, MD, FHRS; Fei Lu, MD, PhD; Cengiz Ermis, MD; Simon Milstein, MD;
Laura Van Heel, RN; Keith G. Lurie, MD; David G. Benditt, MD, FRCPC, FHRS
Background—Clinical experience suggests that atrial tachyarrhythmias (ATs) are a frequent comorbidity in heart failure
patients with left ventricular systolic dysfunction and that volume overload may increase AT susceptibility. However,
substantiating this apparent relationship in free-living patients is difficult. Recently, certain implantable cardioverter-
defibrillators provide, by measuring transpulmonary electric bioimpedance, an index of intrathoracic fluid status
(OptiVol index [OI]). The goal of this study was to determine whether periods of greater intrathoracic fluid congestion
(as detected by OI) correspond with increased AT event frequency.
Methods and Results—This analysis retrospectively assessed the relation between AT events and OI estimate of volume
overload in patients with left ventricular systolic dysfunction and OI-capable implantable cardioverter-defibrillators. OI
values were stratified into 3 levels: group 1, 40; group 2, 40 to 60; and group 3, 60. An OI threshold-crossing event
was defined as OI60, a value previously associated with clinically significant volume overload. Findings in 59 patients
(mean left ventricular ejection fraction, 24%) with 225 follow-up visits (mean, 3.8 visits per patient) were evaluated. AT
prevalence was 73%. AT frequency (percent of patients visits with at least 1 episode of AT since previous device
interrogation) was greater in group 3 versus group 1 (P0.0342). Finally, in terms of temporal sequence, AT episodes
preceded OI threshold-crossing event in 43% of incidences, followed threshold-crossing event in 29%, and was
simultaneous or indeterminate in the remainder.
Conclusions—These findings not only support the view that worsening pulmonary congestion is associated with increased
AT frequency in patients with left ventricular dysfunction but also suggest that AT events may be responsible for
triggering episodic pulmonary congestion more often than previously suspected. (Circ Arrhythmia Electrophysiol.
2009;2:488-494.)
Key Words: bioimpedance  heart failure  atrial tachyarrhythmias  volume overload
Atrial tachyarrhythmias (AT), particularly atrial fibrilla-tion (AF), are a frequent comorbidity in patients with
left ventricular (LV) systolic dysfunction and heart failure.1–5
Further, clinical experience suggests that AT may be trig-
gered by periods of volume overload in such patients.1–5 In
part, AT episodes in this setting may be the consequence of
increased atrial wall stress and/or neurohumoral changes that
often accompany periods of volume overload. Alternatively,
however, it is possible that in certain cases, spontaneous AT
events may be the trigger, by initiating a period of hemody-
namic deterioration and ensuing volume overload.
Clinical Perspective on p 494
The close association of volume overload secondary to LV
systolic dysfunction and AT susceptibility has been estab-
lished primarily during follow-up of patients with chronic
disease1,6,7; documenting such a relationship in acute settings
in free-living individuals is much more difficult. Recently,
however, certain implantable cardioverter-defibrillators
(ICDs) are capable of not only tracking onset and duration of
AT episodes but also monitoring transpulmonary electric
bioimpedance (Z) as an index of intrathoracic fluid volume
status. In the setting of increased intrapulmonary fluid accu-
mulation, transpulmonary bioimpedance tends to fall (ie, due
to the electrolyte-containing fluid exhibiting a lesser imped-
ance to electric current flow than does air).8,9 Conversely, a
reduction of intra-alveolar fluid causes transpulmonary elec-
tric bioimpedance to increase.
At the present time, ICDs capable of assessing transpul-
monary electric bioimpedance use a computed index value
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(OptiVol index [OI], Medtronic Inc, Minneapolis, Minn) that
corresponds to the inverse of a slowly moving average of the
transpulmonary bioimpedance value.8 Thus, a progressively
increasing OI value suggests an increase of intrapulmonary
fluid accumulation.
The purpose of this study was to examine the relationship
between periods of increasing OI, suggesting greater pulmo-
nary congestion, and the occurrence of ICD-documented AT
events in patients with LV systolic dysfunction. We sought to
determine whether AT events tended to be more frequent
during those time periods during which the OI marker
suggested increasing pulmonary vascular overload in patients
with severe LV systolic dysfunction. We further sought to
assess the temporal relation between AT and volume over-
load events.
Methods
This study examined retrospectively findings in consecutive patients
with systolic LV dysfunction who are followed either at University
of Minnesota Medical Center (Minneapolis, Minn) or Central Min-
nesota Heart Center (St Cloud, Minn) and who had implanted either
a conventional or cardiac resynchronization ICD capable of measur-
ing transthoracic electric bioimpedance between the coil of the right
ventricular lead and the metallic shield of the implanted device.
Further, to provide for an adequate follow-up observation period,
findings were restricted to patients with 6 months of follow-up.
Ethics committees at each of the participating institutions approved
the study protocol.
The electric bioimpedance algorithm, summarized by the OI (units
ohms-days), recorded the accumulation of consecutive day-to-day
differences between the current daily and reference transpulmonary
bioimpedance values. Because biological fluid is a better conductor
of electricity than is air, greater intrapulmonary fluid accumulation
reduces transpulmonary electric bioimpedance (Z).9 However, as
noted earlier, for purposes of clinical application a reduced transpul-
monary bioimpedance Z is transposed to provide an increasing OI
value. Thus, increasing OI is indicative of increasing pulmonary
congestion and volume overload.10–13
Study observations, obtained in 59 ambulatory patients, comprised
documenting the correspondence between both AT frequency (per-
cent of visits during which device interrogation showed any episodes
of AT since the immediate previous patient visit with device
interrogations) and AT burden (presented as hours per month as
percentage of total recorded time), and pulmonary congestion (as
assessed by OI value). OI values were stratified (suggesting grada-
tions of pulmonary fluid accumulation), as follows: group 1, 40
(normal range); group 2, 40 to 60 (borderline elevated); and group 3,
60 (markedly elevated). Additionally, we analyzed the temporal
relationship between onset of AT events and the time when OI value
crossed a threshold 60 (threshold crossing event [TCE]). TCE has
been deemed indicative in prior studies of clinically significant
volume overload with regard to hospitalizations for heart failure
(Figure 1).10–13
Patients underwent clinical assessment and device interrogation at
a minimum of every 3 months. Data were obtained from review of
device interrogation recordings for each visit and included duration
of AT episodes and corresponding OI values. All records were
examined independently by 3 of the authors (R.J., G.A.T., D.G.B.).
AT events were those detected by the implanted device and for study
purposes were defined as episodes of duration 5 beats and with
atrial rates 180 bpm. When intra-atrial electrograms showed an
irregular atrial rate 180/min, atrial fibrillation was diagnosed.
However, electrograms were available in only a minority (approxi-
mately 40%) of episodes; consequently, the more general term “AT”
is used.
Data Analysis
The first goal of the study was to assess the correlation between peak
OI (as a marker of volume overload and pulmonary congestion), AT
frequency, and AT burden (defined as the percentage of time a
patient exhibited AT since last follow-up). The second goal of the
Figure 1. A representative tracing with expanded time base acquired from the OI-capable ICD that illustrates approximate coincidence
of AT exacerbations (purple) with abrupt increases of OI values (orange) crossing the threshold of normal (horizontal line) and indicating
pulmonary fluid accumulation in a patient with heart failure. The green line depicts the bioimpedance value (Z0); the red line provides
average baseline reference impedance. Starting from the left of the figure, there are 5 transitions of OI above threshold. The first transi-
tion occurred without AT. AT preceded or coincided with OI crossing threshold in the 2nd and 3rd examples. In the 4th case, the AT
burst occurs after OI increase above threshold. The final OI crossing occurred without AT.
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study was to evaluate the temporal relationship between OI 60 as
a surrogate of marked volume overload and AT episodes.
The patient population was described using descriptive statistics.
Generalized estimating equations (GEEs) with an autoregressive
correlation structure were used to analyze AT frequency (binary
outcome) and AT burden (continuous outcome) to account for
possible correlation between visits within a patient. Univariate and
adjusted analyses were performed. The following covariates were
considered in the adjusted GEE models: group (OI40, 40OI60,
and OI60), age, sex, ejection fraction, cardiomyopathy type,
baseline atrial fibrillation, diabetes mellitus, hypertension, atrial
tachycardia, hyperlipidemia, -blocker therapy, antiarrhythmic drug
therapy, diuretic therapy, statin therapy, angiotensin-converting en-
zyme/adrenergic receptor blocker therapy, aspirin therapy, and
follow-up time.
Patient visits with missing data (outcome or covariates) were
excluded from the analysis. No imputation of missing data was
performed. Finally, the authors note that the AT burden outcome is
a skewed variable because there is a large number of follow-ups in
which patients did not have AT; thus, AT burden was zero.
In the adjusted analyses, backward selection was used and
covariates with probability values 0.10 were retained in the model.
Probability values 0.05 were considered statistically significant.
Statistical analysis was performed using SAS version 9.1.3 (SAS
Institute Inc, Cary, NC).
Results
Patient Population
A total of 69 patients with OI-capable devices were followed
during the time frame of the study. Ten patients were
excluded because of 1 or more of the following: incomplete
data, presence of permanent AT, or ejection fraction 45%.
Table 1 provides demographic data on the remaining 59
patients.
Median follow-up among all patients was 8.6 months
(range, 0.8 to 29.5). The relationships between peak OI and
AT frequency and AT burden were analyzed in 225 patient
visits/device interrogations (mean, 3.8 visits per patient). In 3
instances, the follow-up visits were incomplete with missing
values. These follow-up visits were excluded from analysis.
Total patient visits for each of the 3 OI groups were: group 1,
120; group 2, 61; and group 3, 44. Temporal relationships
between AT and OI were assessed in 41 of 225 patient visits
in which OI was detected to have crossed the threshold of 60
(ie, TCE), and at least 1 episode of AT/AF was observed.
Prevalence of AT
Before device implantation, 30.5% of patients had had prior
AT or AF episodes documented. However, during the course
analysis of the data from device interrogations, 73% of
patients had at least 1 episode of AT or AF, thereby
substantially raising the documented prevalence of AT/AF in
this cohort.
AT Susceptibility and Baseline Features
Clinical factors associated with ICD-documented AT occur-
rences were evaluated. Not surprisingly, a history of atrial
fibrillation was closely associated with greater AT frequency
during follow-up (P0.0200); risk ratio was 2.81 times
higher in the presence of versus the absence of AT history.
On the other hand, whereas female sex was associated with
borderline increased AT odds (P0.0653), other clinical
features including age, LV ejection fraction, and type of
cardiomyopathy were not found by univariate analysis to be
associated with increased AT frequency (P0.5523,
P0.7673, P0.2502, respectively) (Table 2).
OI Versus AT Frequency
The maximum OI was found by univariate analysis to be
significantly associated with greater AT frequency
(P0.0142). AT risk increased as OI increased (odds ratio
[OR]1.007 per 1-U increase; 95% CI, 1.001, 1.013) (Figure
2). In only 20 of 225 or 8.9% of patient visits did TCE 60
occur without a recorded AT episode.
After adjusting for sex, baseline AT history, and use of
antiarrhythmic drugs, and use of diuretic drugs the AT risk
was 2.48 times higher with OI60 compared with OI40
(P0.0425) (Figure 2). OI60 compared with OI between
40 and 60 and OI between 40 and 60 compared with OI40
did not differ significantly with respect to AT risk (P0.2145
and P0.2608, respectively) (Table 3).
Similar results were obtained without including aforemen-
tioned baseline variables in the model (OI60 versus OI40,
OR2.21, P0.0342; OI60 versus OI between 40 and 60,
OR1.78, P0.1278; OI between 40 and 60 versus OI40,
OR1.24, P0.4102).
OI Versus AT burden
Peak OI (coefficient0.03; P0.0110) and use of a
-blocker (coefficient4.7; P0.0399) were found to be
associated with AT burden by univariate analysis from the
GEE model (Figure 3). Other covariates, including OI groups,
were not found to be associated with AT burden.
Temporal Relationships Between AT Events
and OI
The temporal relationship between AT episodes and TCE for
OI (ie, OI60) was examined whenever the 2 occurred
within 2 weeks of each other. This 2-week time period was
chosen to account for the relatively slow cumulative manner
in which OI changes in response to alterations of transpul-
monary Z. This concordance was observed in 34 of 225
(15%) follow-up visits in 21 of 59 (35.6%) of patients.
In most patients, there were examples of all 3 possible
scenarios (Figure 1): AT occurring before TCE (ie, before
presumed clinically significant pulmonary congestion), AT
occurring simultaneous with TCE, and AT episodes occurring
after a TCE. However, AT episode(s) preceding TCE was the
single most frequent finding (43% of incidences or 15 patient
visits). AT episodes after TCE occurred in 29% of episodes or
10 patient visits, and both occurred essentially simultaneously
in 22% or 7 patient visits. In the remaining 6% of instances of
OI excursion above threshold, the temporal relation to AT
events could not be determined with certainty.
Discussion
This study provides 3 principal findings regarding the tem-
poral relationship between episodes of increasing OI (ie,
decreased transpulmonary electric bioimpedance), a marker
of worsening pulmonary congestion, and apparent suscepti-
bility to temporally concordant AT events in patients with LV
systolic dysfunction. First, higher OI values were associated
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with greater likelihood of having an AT event since the most
recent prior patient visit/device interrogation, that is, higher
AT frequency. Second, higher peak OI values were associ-
ated with greater AT duration, that is, higher AT burden.
Table 1. Demographic Information
Statistic n59
Sex
Female n (%) 21 (35.6)
Male n (%) 38 (64.4)
Age, y Mean 64.4
Median 66
SD 12.54
Minimum–maximum 37–87
LV ejection fraction Mean 0.24
Median 0.20
SD 0.10
Minimum–maximum 0.10–0.45
1 missing
Cardiomyopathy
Ischemic n (%) 35 (59.3)
Nonischemic n (%) 24 (40.7)
At least 1 AT episode
Yes n (%) 43 (72.9)
No n (%) 16 (27.1)
Prior AT
Yes n (%) 18 (30.5)
No n (%) 41 (69.5)
Diabetes mellitus
Yes n (%) 16 (28.6)
No n (%) 40 (71.4)
3 missing
Hypertension
Yes n (%) 29 (51.8)
No n (%) 27 (48.2)
3 missing
AT
Yes n (%) 16 (28.6)
No n (%) 40 (71.4)
3 missing
Hyperlipidemia
Yes n (%) 26 (46.4)
No n (%) 30 (53.6)
3 missing
-Blocker
Yes n (%) 52 (92.9)
No n (%) 4 (7.1)
3 missing
Antiarrhythmic
Yes n (%) 15 (26.8)
No n (%) 41 (73.2)
3 missing
Diuretic
Yes n (%) 35 (62.5)
No n (%) 21 (37.5)
3 missing
(Continued)
Table 1. Continued
Statistic n59
Statin
Yes n (%) 37 (66.1)
No n (%) 19 (33.9)
3 missing
ACE/ARB
Yes n (%) 54 (96.4)
No n (%) 2 (3.6)
3 missing
Aspirin n (%)
Yes n (%) 43 (76.8)
No 13 (23.2)
3 missing
ACE/ARB indicates angiotensin-converting enzyme/adrenergic receptor blocker.
Table 2. Univariate Associations With AT Frequency (GEE
Model)
OR 95% CI P Value
Sex, male/female 0.49 0.23 1.05 0.0653
Prior AT, yes/no 2.81 1.18 6.72 0.0200
Age 1.01 0.98 1.05 0.5523
LV ejection fraction 0.55 0.01 29.7 0.7673
Cardiomyopathy, ischemic/nonischemic 0.63 0.28 1.39 0.2502
Diabetes mellitus, yes/no 1.07 0.44 2.59 0.8759
Hypertension, yes/no 1.02 0.45 2.28 0.9680
AT, yes/no 1.92 0.78 4.71 0.1551
Coronary artery disease, yes/no 1.50 0.66 3.41 0.3377
Hyperlipidemia, yes/no 0.63 0.28 1.40 0.2535
-Blocker, yes/no 1.40 0.36 5.41 0.6262
Antiarrhythmic, yes/no 2.48 1.01 6.10 0.0473
Diuretic, yes/no 0.62 0.28 1.38 0.2386
Statin, yes/no 1.78 0.78 4.06 0.1731
ACE/ARB, yes/no 0.98 0.18 5.27 0.9775
Aspirin, yes/no 0.87 0.32 2.31 0.7721
OI 1.007 1.001 1.013 0.0142
Unadjusted GEE model
40OI60 vs OI40 1.24 0.74 2.08 0.4102
OI60 vs OI40 2.21 1.06 4.62 0.0342
OI60 vs 40OI60 1.78 0.85 3.75 0.1278
Adjusted* for prior AT, sex, use of
antiarrhythmic, and diuretic
40OI60 vs OI40 1.40 0.78 2.51 0.2608
OI60 vs OI40 2.48 1.03 5.96 0.0425
OI60 vs 40OI60 1.77 0.72 4.37 0.2145
ACE/ARB indicates angiotensin-converting enzyme/adrenergic receptor blocker.
*Covariates were identified using backward selection, and P values 0.10
were retained in the model.
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Finally, in a subset of patients in whom OI exceeded 60, a
value previously found to be consistent with clinically sig-
nificant heart failure exacerbation,10,–13 AT episodes preceded
(43%) or occurred almost simultaneously (22%), with the
threshold crossing in more than half the patients. Although
timing could not be determined precisely (because OI is a
slowly moving marker of impedance changes), the latter
observation supports the notion that AT may be a relatively
frequent trigger for fluid retention and pulmonary congestion
in patients with LV dysfunction.
It has been generally accepted that in chronic cardiac
disease, LV dysfunction and resultant chronic fluid retention
may predispose individuals to arrhythmias in general and
AT/AF in particular. Several mechanisms have been pro-
posed, including activation of renin-angiotensin-aldosterone
system that promotes fibrosis,14–17 increased atrial
stretch,17–19 and elevated circulating catecholamine levels.17
On the other hand, it is now generally agreed that over time,
sustained AT/AF may adversely affect cardiac function by
cellular and extracellular remodeling, alteration of ion chan-
nel properties,20 and loss of atrial transport.21,22 Whether the
same relationships between volume overload and AT/AF
holds for acute situations is less certain. However, concordant
with clinical experience,1–5 the findings reported here suggest
that acute volume overload may be closely associated with
initiation of AT episodes.
The prevalence of AT in our study population of heart
failure patients with LV dysfunction was thought to be
30.5%, based on medical history obtained before data anal-
ysis. However, based on device interrogations, 73% of our
patients exhibited AT/AF during follow-up. This value is
greater than that found in several large previous clinical trials
(14.4% in the V-HeFT group,23 15.4% in the CHF-STAT
group,24 and 25.8% in DIAMOND CHF group25). Conse-
quently, the true prevalence of AT/AF in patients with LV
dysfunction may be much higher than previously thought. On
the other hand, our patients may have been subject to more
frequent ventricular pacing than would have been the case in
the comparator studies; ventricular pacing has been associ-
ated with greater AT susceptibility. However, the more likely
explanation for the greater AT frequency in this study is that
the implanted devices probably detected many AT events, as
well as shorter AT events, that would have gone undocu-
mented in previous studies in which recordings from im-
planted devices were not routinely available. For instance,
modern ICDs are capable of documenting arrhythmia events,
despite the fact that patients may be asymptomatic; such
events may be missed during conventional clinical follow-up
Figure 2. Graphic illustration of number of patient
visits with and without AT (AT frequency) in the 3
categories of OI patient groups prespecified before
the start of the study. Hatched bars show the
patient visits in which episodes of AT were pres-
ent. White bars show the patient visits in which no
episodes of AT were found. Note that with increas-
ing OI or increasing volume overload, there are
more patient visits with AT relative to patient visits
without AT.
Table 3. AT Burden, AT Hours, and Follow-Up Duration in the 3 OI Groups
Statistic OI40 (n120) OI 40–60 (n51) OI60 (n54)
AT burden, % Mean (SD) 3.8 (17.0) 6.2 (19.8) 7.6 (20.9)
Median (IQR) 0 (0–0.02) 0 (0–0.1) 0.01 (0–3.0)
Minimum–maximum 0–100 0–98.5 0–97.2
AT, h Mean (SD) 37.5 (178.3) 113.5 (366.8) 154.0 (419.0)
Median (IQR) 0 (0–0.2) 0 (0–3.2) 0.18 (0–44)
Minimum–maximum 0–1480 0–2010 0–2570
Follow-up duration, h Mean (SD) 1292.8 (1117.2) 6.2 (19.8) 2939.1 (2032.9)
Median (IQR) 840 (444–2160) 2208 (1680–2928) 2376 (2112–3480)
Minimum–maximum 96–6384 48–4848 336–11616
IQR indicates interquartile range.
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visits, or if only a relatively brief ambulatory ECG monitor-
ing period is relied on (eg, a 48-hour ambulatory ECG).
The observation that 35.6% of our patients had episodes of
AT/AF and clinically significant volume overload (OI60)
occurring within 2 weeks of each other suggest the close
relationship of these 2 clinical conditions in the acute/sub-
acute setting. In nearly one-half of such episodes of pulmo-
nary congestion (defined as OI60), AT may have been the
trigger or at least a complicating factor aggravating the
clinical picture. Our observations suggest that acute volume
overload is often heralded by or closely associated with AT.
In this regard, the factors that trigger AT episodes and may
lead to acute volume overload are not well understood and
may be different from those factors associated with chronic
AT (eg, atrial fibrosis, hypertensive heart disease, valvular
dysfunction, and so on).26–30 Further study of the relation
between acute fluid retention and AT events is warranted.
Indeed, if a close relationship proves to be the case in larger
patient populations, there may be a window of opportunity
(identified by warning from an appropriately programmed
implanted pulse generator or implanted loop recorder) to
address AT episodes and prevent their potential adverse
hemodynamic consequences in patients with LV dysfunction.
Limitations
Several important limitations to this study warrant consider-
ation. First, the correspondence between electric bioimped-
ance changes (such as OI) and clinical heart failure must be
studied more thoroughly in large patient populations. How-
ever, although other technologies are being actively assessed
to detect heart failure episodes at an early stage, electric
bioimpedance is to date the only available surrogate measure
of pulmonary fluid accumulation for use in free-living pa-
tients. Second, this is a retrospective analysis in which we
observed an apparently greater incidence of atrial
tachyarrhythmias than was suggested by the medical history
of prior AT. This may be explained, as indicated earlier, by
the presence of an implanted monitoring device, but could
also have been influenced by our choosing to classify
episodes 5 beats as an AT event. Further, the patient
population was small and as such, we are unable to discern in
this sample whether pulmonary fluid accumulation alone was
responsible for de novo AT. Similarly, the subset analysis
examining temporal relationships between AT and pulmo-
nary congestion was limited by our using the previously
suggested OI60 threshold for diagnosing clinically signifi-
cant volume overload10–13 and by the fact that OI is a slowly
moving average of impedance measurements collected peri-
odically (a necessary limitation in current systems due to the
low level nature of the signal); we can only state whether OI
values and AT events occurred within 2 weeks of each other.
Confirmation of the observation that AT tended to precede
and perhaps trigger volume overload in many cases must be
revisited in a larger population with more precise time
estimates and correlation with emergency room and/or hos-
pital admission data.
Conclusions
In ambulatory patients with LV dysfunction, our findings
suggest that there is a high frequency of AT events and a
potentially clinically important association between diminish-
ing transpulmonary electric bioimpedance (ie, increasing OI
suggesting worsening pulmonary fluid volume status) and
increased susceptibility to AT events. Further, our findings
document in free-living individuals that AT episodes may be
an underappreciated but possibly important trigger for acute
pulmonary congestion/volume overload. Potentially, if larger
studies substantiate the relationships observed here, a treat-
ment strategy designed to reduce AT risk and/or detect and
foreshorten AT episodes may prove beneficial for reducing
susceptibility to pulmonary congestion in patients with LV
systolic dysfunction.
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CLINICAL PERSPECTIVE
Atrial tachyarrhythmias (AT), particularly atrial fibrillation (AF), occur frequently in patients with heart disease and left
ventricular dysfunction. Clinical experience suggests that AT/AF susceptibility is increased during periods of worsening
heart failure, a condition typically associated with excess fluid volume in the lungs. However, the apparently close
association between heart failure and AT/AF has been established primarily during follow-up of patients with chronic
disease; documenting such a relationship in acute settings of heart failure exacerbation in free-living individuals is much
more difficult. Recently, however, certain implantable cardioverter-defibrillators are capable of not only tracking onset and
duration of AT/AF episodes but also estimating transpulmonary electric bioimpedance as an index of intrathoracic fluid
volume status. Using this recently introduced technology, findings in this study support the view that there is a clinically
important association between worsening pulmonary fluid volume status (as assessed by diminishing transpulmonary
electric bioimpedance) and increased susceptibility to AT/AF events in free-living individuals. In addition, our findings
suggest that AT/AF episodes may be an underappreciated but an important trigger for acute pulmonary congestion/volume
overload. Potentially, if larger studies substantiate the relationships observed here, a treatment strategy designed to reduce
AT risk and/or detect and foreshorten AT episodes may prove beneficial for reducing susceptibility to pulmonary
congestion in certain patients with heart failure.
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